NEW YORK, Sept. 8, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced its participation at two upcoming investment conferences this month. Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the Rodman & Renshaw Annual Global Investment Conference, being held at the St. Regis Hotel in New York City, tomorrow September 9, 2015 at 3:00pm ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
On Thursday, September 10, 2015 at 8:15am ET, Mr. Weiss will participate in a panel discussion at the Wells Fargo Securities 2015 Healthcare Conference being held at the Hyatt Regency in Boston, MA. This event will not be webcast.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop IRAK4 inhibitors, as well as an antibody research program to develop anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
TGTX - G